Effect of inhaled formoterol and budesonide on exacerbations of asthma

New England Journal of Medicine

Volumn 337, Issue 20, 1997, Pages 1405-1411

  Pauwels, Romain A ^a   Löfdahl, Claes Göran ^b   Postma, Dirkje S ^c   Tattersfield, Anne E ^d   O'Byrne, Paul ^e   Barnes, Peter J ^f   Ullman, Anders ^g  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^e MCMASTER UNIVERSITY   (Canada)

^f NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^g ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; FORMOTEROL; GLUCOCORTICOID; TERBUTALINE;

ADULT; AGED; ARTICLE; ASTHMA; BETA ADRENERGIC STIMULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN TISSUE; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEROID THERAPY;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; AGED; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE;

EID: 1842370350     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199711133372001     Document Type: Article

References (35)

1. 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991;325:388-92.
2. van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, Duiverman EJ, Pocock SJ, Kerrebijn KF. Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. Am Rev Respir Dis 1992;146: 547-54.
3. Global Initiative for Asthma. Global strategy for asthma management and prevention. Washington, D.C.: National Heart, Lung, and Blood Institute, 1995. (Publication no. 95-3659.)
4. Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990;336:1391-6.
5. Spitzer WO, Suissa S, Ernst P, et al. The use of β-agonist and the risk of death and near death from asthma. N Engl J Med 1992;326:501-6.
6. Drazen JM, Israel E, Boushey HA, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. N Engl J Med 1996;335:841-7.
7. Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 1992;327:1420-5.
8. Kesten S, Chapman KR, Broder I, et al. A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. Am Rev Respir Dis 1991;144:622-5.
9. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994;344:219-24.
10. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153:1481-8.
11. Kalra S, Swystun VA, Bhagat R, Cockcroft DW. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest 1996;109:953-6.
12. Bhagat R, Kalra S, Swystun VA, Cockcroft DW. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest 1995;108:1235-9. [Erratum, Chest 1996;109:592.]
13. 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992;327:1198-203.
14. Ramage L, Lipworth BJ, Ingram CG, Cree IA, Dhillon DP. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 1994;88:363-8.
15. Newnham DM, McDevitt DG, Lipworth BJ. Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. Am J Med 1994;97:29-37.
16. 2-agonists in asthma. N Engl J Med 1992;327: 1204-8.
17. Tattersfield AE. Clinical pharmacology of long-acting beta-receptor agonists. Life Sci 1993;52:2161-9.
18. Cockcroft DW, Swystun VA, Bhagat R. Interaction of inhaled beta 2 agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine. Am J Respir Crit Care Med 1995;152:1485-9.
19. Yates DH, Sussman HS, Shaw MJ, Barnes PJ, Chung KF. Regular formoterol treatment in mild asthma: effect on bronchial responsiveness during and after treatment. Am J Respir Crit Care Med 1995;152:1170-4.
20. Lofdahl CG, Svedmyr N. Beta-agonists - friends or foes? Eur Respir J 1991;4:1161-5.
21. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows: report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal: official statement of the European Respiratory Society. Eur Respir J 1993;6:Suppl 16:5-40.
22. Roberts JA, Bradding P, Walls AF, et al. The influence of salmeterol xinafoate on mucosal inflammation in asthma. Am Rev Respir Dis 1992; 145:Suppl:A418. abstract.
23. Gardiner PV, Ward C, Booth H, Allison A, Hendrick DJ, Walters EH. Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. Am J Respir Crit Care Med 1994; 150:1006-11.
24. Turner MO, Hussack P, Sears MR, Dolovich J, Hargreave FE. Exacerbations of asthma without sputum eosinophilia. Thorax 1995;50:1057-61.
25. Fahy JV, Kim KW, Liu J, Boushey HA. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol 1995;95:843-52.
26. Whelan CJ, Johnson M, Vardey CJ. Comparison of the anti-inflammatory properties of formoterol, salbutamol and salmeterol in guinea-pig skin and lung. Br J Pharmacol 1993;110:613-8.
27. Erjefalt I, Persson CG. Long duration and high potency of antiexudative effects of formoterol in guinea-pig tracheobronchial airways. Am Rev Respir Dis 1991;144:788-91.
28. Advenier C, Qian Y, Koune JD, Molimard M, Candenas ML, Naline E. Formoterol and salbutamol inhibit bradykinin- and histamine-induced airway microvascular leakage in guinea-pig. Br J Pharmacol 1992;105:792-8.
29. Baluk P, McDonald DM. The beta 2-adrenergic receptor agonist formoterol reduces microvascular leakage by inhibiting endothelial gap formation. Am J Physiol 1994;266:L461-L468.
30. Kallstrom BL, Sjoberg J, Waldeck B. The interaction between salmeterol and beta 2-adrenoceptor agonists with higher efficacy on guinea-pig trachea and human bronchus in vitro. Br J Pharmacol 1994;113:687-92.
31. Britton MG, Earnshaw JS, Palmer JBD. A twelve month comparison of salmeterol with salbutamol in asthmatic patients. Eur Respir J 1992;5: 1062-7. [Erratum, Eur Respir J 1993;6:150.]
32. Kesten S, Chapman KR, Broder I, et al. Sustained improvement in asthma with long-term use of formoterol fumarate. Ann Allergy 1992;69: 415-20.
33. Verberne AAPH, Frost C, Roorda RJ, van der Laag H, Kerrebijn KF, Dutch Paediatric Asthma Study Group. One year treatment with salmeterol compared with beclomethasone in children with asthma. Am J Respir Crit Care Med 1997;156:688-95.
34. Thorsson L, Edsbacker S, Conradson TB. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J 1994;7:1839-44.
35. Borgstrom L, Derom E, Stahl E, Wahlin-Boll E, Pauwels R. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med 1996;153:1636-40.